The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of age and medical comorbidity (MC) on adjuvant treatment outcomes for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials.
Daniel G. Haller
Consultant or Advisory Role - Roche; Sanofi
Honoraria - Roche
Michael O'Connell
No relevant relationships to disclose
Thomas H. Cartwright
Consultant or Advisory Role - Genentech; Roche
Honoraria - Genentech; Roche
Christopher Twelves
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Edward McKenna
Employment or Leadership Position - Genentech
Weijing Sun
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Wasif M. Saif
Honoraria - Amgen; Bristol-Myers Squibb; Genentech; Lilly
Research Funding - Clovis Oncology; Genentech; Gilead Sciences; Infinity; Newlink Genetics; Roche
Luen F. Lee
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Greg Yothers
Consultant or Advisory Role - Roche/Genentech (U)
Hans-Joachim Schmoll
Consultant or Advisory Role - Merck; Roche
Honoraria - Merck; Roche